Citi Starts Telix Pharmaceuticals Ltd (TLX) at Buy
Tweet
Share
E-mailGet Alerts TLX Hot Sheet
Price: $11.33 -8.78%
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
4 Buy, 1 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Citi analyst Laura Sutcliffe initiates coverage on Telix Pharmaceuticals Ltd (NASDAQ: TLX) with a Buy rating and a price target of $22.00.
For an analyst ratings summary and ratings history on Telix Pharmaceuticals Ltd click here. For more ratings news on Telix Pharmaceuticals Ltd click here.
Shares of Telix Pharmaceuticals Ltd closed at $9.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
- Solowin Holdings marks 10 years, expands into stablecoins and AI
- Alzamend Neuro (ALZN) files for 98.4M share offering by selling stockholders
Create E-mail Alert Related Categories
New CoverageRelated Entities
Citi, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
